Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG...
Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706: Therapy
About this item
Full title
Author / Creator
Hussein, M A , Gundacker, H , Head, D R , Elias, L , Foon, K A , Boldt, D H , Dobin, S M , Dakhil, S R , Budd, G T and Appelbaum, F R
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
B-cell chronic lymphocytic leukemia (CLL) accounts for 95% of chronic leukemia cases and 25% of all leukemia. Despite the prevalence of CLL, progress in its treatment has been only modest over the past three decades. Based upon the ability of fludarabine to produce high-grade remissions especially among patients with low initial tumor mass, and the...
Alternative Titles
Full title
Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706: Therapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_springer_journals_10_1038_sj_leu_2403940
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_springer_journals_10_1038_sj_leu_2403940
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/sj.leu.2403940
